S&P Futures
3,860.25 +12.00 (+0.31%) Dow Futures
31,105.00 +92.00 (+0.30%) Nasdaq Futures
11,936.50 +56.25 (+0.47%) Russell 2000 Futures
1,735.50 +6.90 (+0.40%) Crude Oil
98.82 +0.29 (+0.29%) Gold
1,740.90 +4.40 (+0.25%)
Seagen Inc. (SGEN)
Pre-Market:
Chart Events
Performance Outlook
| Previous Close | 176.77 |
| Open | 175.63 |
| Bid | 0.00 x 1100 |
| Ask | 0.00 x 900 |
| Day's Range | 174.51 - 179.00 |
| 52 Week Range | 105.43 - 192.79 |
| Volume | |
| Avg. Volume | 1,419,386 |
| Market Cap | 32.024B |
| Beta (5Y Monthly) | 0.82 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.84 |
| Earnings Date | Apr 27, 2022 - May 02, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 159.88 |
- The Wall Street Journal
Merck Is in Advanced Talks to Buy Seagen for Roughly $40 Billion or More
A deal, potentially worth $40 billion or more, would help Merck broaden its lineup of cancer drugs, currently led by Keytruda.
- TipRanks
These 2 Tech Winners Could Reach New Highs, Says Jim Cramer
There’s no doubt about it, the tech sector, which powered so much of the market’s success in the last decade, has led the declines in the past six months. Since the start of the year, the tech-heavy NASDAQ index is down nearly 28%, even after some recent bounces. But while the index is beaten down, not every component stock is suffering right now. Some stocks, in fact, have been outperforming their peers, and haven’t been touched by the general collapse in tech. Jim Cramer, the well-known host o
- Business Wire
Seagen Announces Results from Pivotal MOUNTAINEER Trial Demonstrating Clinically Meaningful Antitumor Activity of TUKYSA® (tucatinib) in Combination with Trastuzumab in Previously Treated HER2-Positive Metastatic Colorectal Cancer
BOTHELL, Wash., July 02, 2022--Seagen Inc. (Nasdaq:SGEN) today announced full results from the pivotal phase 2 MOUNTAINEER trial, which showed TUKYSA® (tucatinib) in combination with trastuzumab was well-tolerated with durable responses in patients with previously treated HER2-positive metastatic colorectal cancer (mCRC). These late-breaking data were presented in an oral session at the European Society for Medical Oncology (ESMO) World Congress on Gastrointestinal Cancer on July 2 in Barcelona,
